Compare ASUR & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | TNYA |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.9M | 234.8M |
| IPO Year | 1992 | 2021 |
| Metric | ASUR | TNYA |
|---|---|---|
| Price | $8.92 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $13.60 | $8.00 |
| AVG Volume (30 Days) | 99.7K | ★ 5.1M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $132,022,000.00 | N/A |
| Revenue This Year | $19.20 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.54 | N/A |
| 52 Week Low | $7.63 | $0.36 |
| 52 Week High | $12.74 | $3.69 |
| Indicator | ASUR | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 66.09 | 27.57 |
| Support Level | $8.62 | $0.79 |
| Resistance Level | $8.99 | $1.46 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 91.82 | 3.40 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its HCM products majorly in the United States.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.